

## CLASSIFIED ADVERTISING

Classified advertising orders, correspondence and payments should be directed to: JABFP, Classified Advertising, 1440 Main Street, Waltham, MA 02154.

Classified advertisements placed with JABFP are restricted to physician recruitment, faculty positions, CME courses/seminars, and practices for sale. All ads must relate to the medical field and are subject to approval.

Please refer to the schedule below for closing dates. Classified rate is \$1.40 per word (minimum charge of \$75.00 per ad insertion) and \$95.00 per column inch for classified display ads. Prepayment in full is required with all classified advertising. We accept American Express, VISA, or MasterCard. Confidential reply boxes are an additional \$10.00 per insertion. Responses are sent directly every Tuesday and Thursday and the box will remain open for three months.

All advertisements for employment must be non-discriminatory and comply with all applicable laws and regulations. Ads that discriminate against applicants based on sex, age, race, religion, marital status or physical handicap will not be accepted.

NOTE: Our classified advertisements are all set in the same typeface and format. All ads are highlighted by geographic territory.

For more information please call (800) 635-6991 (outside MA), (617) 893-3800 (In MA). Fax # (617) 893-5003.

Issue Date	Closing Date	Issue Date	Closing Date
Jan.-Feb.	Dec. 1, 1992	March-Apr.	Feb. 1, 1993
May.-June	Apr. 1, 1993	July-Aug.	June 1, 1993
Sept.-Oct.	Aug. 2, 1993	Nov.-Dec.	Oct. 1, 1993

### NORTHEAST

**NEW HAMPSHIRE, NASHUA** — A full-time emergency department staff physician is sought for Level II, 218-bed hospital in Nashua. Requirements include Board certification in emergency medicine or a primary care specialty. High-limit occurrence-based malpractice insurance is offered plus a very competitive hourly fee. Situated in southern New Hampshire, Nashua is only 30 miles from Boston and one hour to the Atlantic Ocean. Three ski areas are located nearby. Nashua boasts a population of over 80,000, and has a strong economic base. If you are interested in hearing more about this emergency medicine position in Nashua, please contact Denise Johnson, Spectrum Emergency Care, P.O. Box 27352, St. Louis, MO 63141; 1-800-325-3982, ext. 3017.

**NEW ENGLAND** — Leading community teaching hospital in the block for 18 years positioned as the 6th largest hospital in state for discharges has expanded its base for Family Practitioners. Become involved with a forward thinking organization with all leading technology and subspecialties available. Be part of an integrated healthcare system including a children's hospital and rehab center. Aggressive salary guarantees, benefits and support. Ideal blend of practice and lifestyle. Offers diverse cultural, educational, and recreational activities. Live by the ocean and have easy commute to metropolitan city and mountain resorts. Ann Breitner 1-800-658-4225.

### MIDWEST

**FAMILY PRACTICE** — Faculty Development Fellowships in Academic Medicine and Clinical Investigation and Geriatrics. The Department of Family Practice and Community Health, Medical School, University of Minnesota, invites applicants for two two-year, full-time family practice fellowship programs. The Fellowship in Academic Medicine and Clinical Investigation is designed to develop full-time family physician faculty and offers opportunities in academic teaching, research, and ad-

ministration, combined with opportunities for acculturation to an academic milieu and continuing development of clinical skills. The Geriatrics Fellowship Program prepares individuals for leadership in academic geriatric medicine and offers a wide variety of opportunities for clinical and academic training and research involvement. Both Fellowships offer the opportunity to earn an additional degree (e.g., MPH). Qualifications include Minnesota licensure eligibility, ABFP/ABIM Certification or eligibility as practicing physician, evidence of professional goals and values consistent with a full-time career in Academic Medicine. Fellowship awards begin on July 1, 1993 with annual stipend of \$38,000 and tuition. For additional information and application materials, contact: Edward W. Ciriacy, M.D., Professor and Head, Department of Family Practice and Community Health, University of Minnesota Medical School, Box 381 UMHC, Minneapolis, Minnesota 55455. Please specify the program(s) in which you are interested. The University of Minnesota is an equal opportunity educator and employer.

### PACIFIC

**FACULTY POSITIONS** — Northern California - Assistant Directorship available at a U.C. Davis affiliated Family Practice Program located in Stockton, California. The program is fully accredited within 18 residents. Candidates must be Board eligible or Board certified. Responsibilities include resident teaching, patient care and administration. AA/EOE. Please send CV to: Asma Jafri, M.D., P.O. Box 1020, Stockton, CA 95201. FAX 209-468-6747, Phone 209-468-6834.

**CENTRAL WASHINGTON STATE** — New University of Washington affiliated Family Practice residency program in Yakima, WA. Program will start July 1993. Seeking qualified Family Physician faculty to begin Winter/Spring '93. Community of 60,000 (service population 200,000) located in Eastern foothills of the North Cascades, two hours East of Seattle. Program jointly sponsored by two 200-bed community hospitals. Competitive salary/benefits. Supportive and collegial medical community. OB skills preferred. Program emphasis includes rural and underserved practice. Please contact Mike Maples, MD, Director, P.O. Box 361, Yakima, WA 98907. Phone 509-966-6860.

### SOUTHEAST

**FAMILY PRACTICE** — Alabama, Arizona, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, Missouri, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia, Wisconsin. We have more than 50 openings for BC/BE Family Practice physicians in solo, partnership, group, clinic, or HMO positions in urban, suburban, and rural communities! Send CV in confidence to Physician Placement Service of America, 330 Franklin Rd., Box 897, Brentwood, TN 37024-0897 or call Margaret Fite at (800) 359-7421.

### SOUTHWEST

**FAMILY PRACTITIONER** — Two-physician practice is looking for family practitioner. Practice includes OB, surgery, and medical management skills. Position offers attractive salary with early full partnership, three weeks vacation, two weeks CME, and paid malpractice coverage. Local hospital ER has primary coverage by PA, call coverage is minimal. Nestled between two spring-fed streams and surrounded by numerous lakes, our location offers a wide variety of outdoor recreational opportunities only a few minutes from town. The community is delightfully small (3,500), with a very good school system, a two-year junior college, an active chamber of commerce, and a community theater group. We are only 30 minutes from a four-year university. Dallas and Oklahoma City are both within two hours. Contact Patrick A. Bell, M.D., Bell Clinic, Inc., P.O. Box 8, Tishomingo, OK 73460, (405) 371-2343.



# NOW you can HEAR what you've been missing!

**Announcing Journal Watch - The Audio Cassette Service — the fastest way to keep up with what's new and important in medicine**



Twice a month, Journal Watch — The Audio Cassette Service brings you 60 minutes of clear, concise summaries of the latest advances published in more than 20 major journals.

Journal Watch — The Audio Cassette Service is written exclusively by practicing physicians. With your subscription you can earn two Category I CME credits per one hour program — at no additional cost.

Using Journal Watch's convenient, easy to listen to audio cassettes, you can schedule when and where to listen.

- In your car
- At the gym
- During meal time
- Between patients
- During your daily routines
- Or simply spare moments of the day

Brought to you by two leaders in medical information — Audio-Digest Foundation, producers of "The Thirteen Spoken Medical Journals®" and the Massachusetts Medical Society, publishers of the *New England Journal of Medicine*, *Journal Watch* (the newsletter), and *AIDS Clinical Care*.



## FREE SAMPLE CASSETTE!

**YES!** Please rush my FREE sample cassette, Volume 1, Issue 1 of Journal Watch — The Audio Cassette Service. If I decide to become a charter subscriber, I'll receive 9 months, 18 issues at the special introductory price of \$113.75.

NAME \_\_\_\_\_ (PLEASE PRINT)  
 ADDRESS \_\_\_\_\_  
 CITY \_\_\_\_\_  
 STATE \_\_\_\_\_ ZIP \_\_\_\_\_

Mail to:  
**Audio-Digest Foundation®**  
 A Non-Profit Subsidiary of the California Medical Association  
 1577 East Chevy Chase Drive  
 Glendale, CA 91206

Or  
**Call Toll Free:**  
**1-800-423-2308**  
 (8 am to 5 pm, Pacific Time)  
**FAX Toll Free:**  
**1-800-845-4375**  
 (24 hours)




*L.DL/HDL Ratios serum lipoproteins*

# NEW!

## MEDICAL USES OF STATISTICS

### SECOND EDITION

John C. Bailar III, M.D., Ph.D.,  
McGill University;  
and Frederick Mosteller, Ph.D.,  
Harvard School of Public  
Health; with 32  
distinguished contributors



# SECOND EDITION!

## A Practical Approach to Statistics

Can you evaluate the validity of published studies?

Do you know when and why to use certain statistical techniques?

Bailar & Mosteller provide you with the expert guidance you need.

If you've been looking for an overview of medical statistics that's understandable, easy to apply, and up-to-date, order your own copy today!

©1992, 480 pages, 90 illus., paperback  
ISBN 0-910133-36-0

### Contents: Revised & Updated — Plus 7 New Chapters

- **Broad Concepts and Analytical Techniques**  
The basic principles behind statistical techniques with a *new* chapter on uses of statistical thinking.
- **Design**  
The strengths and weaknesses in current research design.
- **Analysis**  
How to evaluate statistical tools—with *new* chapters on decision analysis, statistical analysis of survival data, and contingency tables in medical studies.
- **Communicating Results**  
How to present the data clearly—plus *new* guidelines for statistical reporting in medical journals.
- **Reviews and Meta-studies**  
How to appraise research and analyze data combined from several studies. Plus *new* chapters on medical technology assessment and an update of the quality and methodology of meta-analysis.

- YES**, send me a copy of the new Second Edition of *Medical Uses of Statistics* for my risk-free trial.
- Check enclosed for \$39.95,\* plus \$3.50 postage and handling. (Make check payable to NEJM Books)  
(\*Massachusetts Residents add 5% sales tax.)
- Charge my  VISA  MasterCard  AmEx

CARD NO. \_\_\_\_\_  
EXP. DATE \_\_\_\_\_

SIGNATURE \_\_\_\_\_  
SDSF1 REQUIRED FOR CHARGE ORDERS

NAME/SPECIALTY \_\_\_\_\_ (PLEASE PRINT)  
FROM \_\_\_\_\_  
ADDRESS \_\_\_\_\_  
CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_

**SATISFACTION GUARANTEED**  
You must be completely satisfied with the Second Edition of *Medical Uses of Statistics* or you may return the book within 30 days and receive a FULL REFUND.

Please allow 4-6 weeks for delivery:  
Send to: **NEJM BOOKS**  
The New England Journal of Medicine  
P.O. Box 9130, Waltham, MA 02254-9130  
or call 1-800-THE-NEJM FAX: 617-893-0413



# Sectral<sup>®</sup> 200 mg 400 mg CAPSULES

## acebutolol HCl

THE (CARDIOSELECTIVE) BETA BLOCKER FOR PVC CONTROL

<b>Usual starting dose</b>	200 mg b.i.d.
<b>Optimal PVC response</b>	600 mg to 1200 mg per day
<b>Use in elderly</b>	Doses above 800 mg per day should be avoided

(Brief Summary. See Package Circular for full prescribing information.)

**CONTRAINDICATIONS:** SECTRAL is contraindicated in: 1) persistently severe bradycardia, 2) second- and third-degree heart block, 3) overt cardiac failure, 4) cardiogenic shock. (See WARNINGS)

**WARNINGS: Cardiac Failure:** Sympathetic stimulation may be essential for support of circulation in patients with diminished myocardial contractility and inhibition by  $\beta$ -adrenergic receptor blockade may precipitate more severe failure. Although  $\beta$ -blockers should be avoided in overt cardiac failure, SECTRAL can be used cautiously when heart failure is controlled with digitalis and/or diuretics. Digitalis and SECTRAL impair AV conduction. Withdraw SECTRAL if cardiac failure persists.

**In Patients Without a History of Cardiac Failure:** In patients with aortic or mitral valve disease or compromised left ventricular function, continued depression of the myocardium with  $\beta$ -blockers over time may lead to cardiac failure. Digitalize patients at first signs of failure, and/or give a diuretic and observe closely. Withdraw SECTRAL if cardiac failure persists.

**Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal:** Abrupt discontinuation of some  $\beta$ -blockers in coronary artery disease patients may exacerbate angina, in some cases, myocardial infarction and death have been reported. Caution such patients against interruption of therapy without a physician's advice. Even in the absence of overt ischemic heart disease, withdraw SECTRAL gradually over a period of about two weeks, observe carefully and advise patients to minimize physical activity during this time. (If desired, patients may be transferred directly to comparable doses of an alternative  $\beta$ -blocker without interruption of  $\beta$ -blocking therapy.) If exacerbation of angina occurs, restart full-dose anti-anginal therapy immediately and hospitalize patient until stabilized.

**Peripheral Vascular Disease:**  $\beta$ -antagonists reduce cardiac output and can precipitate/aggravate arterial insufficiency in patients with peripheral or mesenteric vascular disease. Exercise caution and observe such patients closely for progression of arterial obstruction.

**Bronchospastic Diseases: Patients with Bronchospastic Diseases Should, in General, Not Receive a  $\beta$ -Blocker.** Because of its relative  $\beta_1$ -selectivity, low doses of SECTRAL may be used cautiously in such patients who do not respond to, or cannot tolerate, alternative treatment. Since  $\beta_1$ -selectivity is not absolute and is dose-dependent, use lowest possible dose of SECTRAL initially, preferably in divided doses. Make bronchodilator, e.g., theophylline, or a  $\beta_2$ -stimulant, available in advance with instructions for use.

**Anesthesia and Major Surgery:** The necessity/desirability of withdrawing  $\beta$ -blockers prior to major surgery is controversial; the heart's impaired ability to respond to  $\beta$ -adrenergically mediated reflex stimuli may enhance the risk of excessive myocardial depression during general anesthesia. Difficulty in restarting and maintaining the heartbeat also has been reported with  $\beta$ -blockers. If treatment is continued, take special care when using anesthetics that depress the myocardium; use lowest possible SECTRAL dose. SECTRAL, like other  $\beta$ -blockers, is a competitive inhibitor of  $\beta$ -receptor agonists, so its effects can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol). Symptoms of excessive vagal tone (e.g., profound bradycardia, hypotension) may be corrected with atropine.

**Diabetes and Hypoglycemia:**  $\beta$ -blockers may potentiate insulin-induced hypoglycemia and mask some symptoms such as tachycardia, dizziness and sweating are usually not significantly affected. Warn diabetics of possible masked hypoglycemia.

**Thyrotoxicosis:**  $\beta$ -adrenergic blockade may mask some clinical signs (tachycardia) of hyperthyroidism. Abrupt withdrawal of SECTRAL may precipitate a thyroid storm in patients suspected of developing thyrotoxicosis.

**PRECAUTIONS: Impaired Renal or Hepatic Function:** While there are no U.S. studies, foreign published experience shows that acebutolol has been used successfully in chronic renal insufficiency. Acebutolol is excreted via the G.I. tract, but the active metabolite, diacetolol, is eliminated mainly by the kidney. A linear relationship exists between renal clearance of diacetolol and creatinine clearance ( $Cl_{cr}$ ); reduce daily dose of acebutolol by 50% when  $Cl_{cr}$  is less than 50 mL/min and by 75% when it is less than 25 mL/min. Use cautiously in patients with impaired hepatic function.

SECTRAL has been used successfully and without problems in elderly patients in U.S. clinical trials without specific dosage adjustment. However, in the elderly, lower maintenance doses may be required because bioavailability of SECTRAL and its metabolite are approximately doubled.

**Information for Patients:** Warn patients, especially those with evidence of coronary artery disease, against interruption or discontinuation of SECTRAL without physician supervision. Although cardiac failure rarely occurs in properly selected patients, advise patients to consult a physician if signs or symptoms suggestive of impending CHF, or unexplained respiratory symptoms, develop.

Warn patients of possible severe hypertensive reactions from concomitant use of  $\alpha$ -adrenergic stimulants, e.g., nasal decongestants used in OTC cold medicines and nasal drops.

**Clinical Laboratory Findings:** SECTRAL, like other  $\beta$ -blockers has been associated with development of antinuclear antibodies (ANA). In prospective clinical trials, patients receiving SECTRAL had a dose-dependent increase in the development of positive ANA titers. Symptoms related to this laboratory abnormality were infrequent. Symptoms and ANA titers were reversible upon discontinuation of SECTRAL.

**Drug Interactions:** Catecholamine-depleting drugs may have additive effects when given with  $\beta$ -blockers. Observe patients treated with both agents closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia. Exaggerated hypertensive responses have been reported from use of  $\beta$ -adrenergic antagonists with  $\alpha$ -adrenergic stimulants, including those in OTC cold remedies and vasoconstrictive nasal drops. Nonsteroidal anti-inflammatory drugs may blunt antihypertensive effects of  $\beta$ -blockers.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Chronic oral toxicity studies in rats and mice, at doses 15 times the maximum recommended (60 kg) human dose, did not indicate carcinogenic potential for SECTRAL. Diacetolol, the major metabolite in man, was without carcinogenic potential in rats at doses up to 1800 mg/kg/d. SECTRAL and diacetolol also had no mutagenic potential in the Ames Test. No significant impact on reproductive performance or fertility was found in rats following SECTRAL or diacetolol doses of up to 240 or 1000 mg/kg/d, respectively.

**Pregnancy: Teratogenic Effects:** Pregnancy Category B: No teratogenic effects were seen in rat or rabbit reproduction studies utilizing SECTRAL doses that were, respectively, approximately 31.5 and 6.8 times the maximum recommended human dose. At this dose in the rabbit, slight fetal growth retardation was noted; this was considered to be a result of maternal toxicity (evidenced by reduced food intake, lowered rate of body weight gain, mortality). Diacetolol studies (doses up to 450 mg/kg/d in rabbits and up to 1800 mg/kg/d in rats) showed no evidence of fetal harm other than a significant elevation in postimplantation loss with 450 mg/kg/d, a level at which food consumption and body weight gain were reduced in rabbit dams; there was a nonstatistically significant increase in incidence of bilateral cataract in rat fetuses from dams treated with 1800 mg/kg/d. There are no adequate and well-controlled trials in pregnant women; SECTRAL should be used during pregnancy only if potential benefit justifies risk to the fetus.

**Nonteratogenic Effects:** Human studies indicate that acebutolol and diacetolol cross the placenta. Neonates of mothers who received acebutolol during pregnancy have reduced birth weight, decreased blood pressure, and decreased heart rate.

**Labor and Delivery:** Effect on labor and delivery in pregnant women is unknown. Animal studies have shown no effect of SECTRAL on the usual course of labor and delivery.

**Nursing Mothers:** Acebutolol and diacetolol appear in breast milk (milk: plasma ratio of 7.1 and 12.2, respectively). Use in nursing mothers is not recommended.

**Pediatric Use:** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS:** SECTRAL is well tolerated in properly selected patients. Most adverse effects have been mild, not required therapy discontinuation, and tended to decrease as treatment duration increases.

The incidence of treatment-related side effects (volunteered and elicited) derived from U.S. controlled clinical trials in patients with hypertension, angina and arrhythmia follows. Numbers represent percentage incidence for SECTRAL (N = 1002) versus placebo (N = 314), respectively

**Cardiovascular:** Chest pain 2%, 1%; Edema 2%, 1%. **CNS:** Depression 2%, 1%, Dizziness 6%, 2%; Fatigue 11%, 4%; Headache 6%, 4%; Insomnia 3%, 1%; Abnormal dreams 2%, 1%. **Dermatologic:** Rash 2%, 1%. **Gastrointestinal:** Constipation 4%, 0%, Diarrhea 4%, 1%; Dyspepsia 4%, 1%; Flatulence 3%, 1%; Nausea 4%, 0%. **Genitourinary:** Micturition (frequency) 3%, <1%. **Musculoskeletal:** Arthralgia 2%, 2%; Myalgia 2%, 0%. **Respiratory:** Cough 1%, 0%; Dyspnea 4%, 2%; Rhinitis 2%, <1%. **Special Senses:** Abnormal Vision 2%, 0%

The following selected (potentially important) side effects were seen in up to 2% of SECTRAL patients: **Cardiovascular:** hypotension, bradycardia, heart failure, anxiety hyper/hypoesthesia, impotence. **Skin:** pruritus. **Gastrointestinal:** vomiting, abdominal pain. **Genitourinary:** dysuria, nocturia. **Liver and Biliary:** small number of reported cases of liver abnormalities (increased SGOT, SGPT, LDH). In some cases, increased bilirubin or alkaline phosphatase, fever, malaise, dark urine, anorexia, nausea, headache, and/or other symptoms have been reported. In some cases, symptoms and signs were confirmed by rechallenge. Abnormalities were reversible upon drug cessation. **Musculoskeletal:** back and joint pain. **Respiratory:** pharyngitis, wheezing. **Special Senses:** conjunctivitis, dry eye, eye pain. **Autoimmune:** extremely rare reports of systemic lupus erythematosus.

Incidence of drug-related adverse effects (volunteered and solicited) based on SECTRAL dose is shown below. (Data from 266 hypertensive patients treated for 3 months on a constant dose.)

Body System	400 mg/day (N = 132)	800 mg/day (N = 63)	1200 mg/day (N = 71)
Cardiovascular	5%	2%	1%
Gastrointestinal	3%	3%	7%
Musculoskeletal	2%	3%	4%
Central Nervous System	9%	13%	17%
Respiratory	1%	5%	6%
Skin	1%	2%	1%
Special Senses	2%	2%	6%
Genitourinary	2%	3%	1%

**Potential Adverse Effects:** Certain adverse effects not listed above have been reported with other  $\beta$ -blocking agents and should be considered as potential adverse effects of SECTRAL.

**CNS:** Reversible mental depression progressing to catatonia, an acute syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuro-psychometrics.

**Cardiovascular:** Intensification of AV block (see CONTRAINDICATIONS). **Allergic:** Erythematous rash, fever with aching and sore throat, laryngospasm, respiratory distress.

**Hematologic:** Agranulocytosis, nonthrombocytopenic and thrombocytopenic purpura. **Gastrointestinal:** Mesenteric arterial thrombosis, ischemic colitis.

**Miscellaneous:** Reversible alopecia, Peyronie's disease. The oculomucocutaneous syndrome associated with praloxolol has not been reported with SECTRAL.

**Keep at room temperature, Approximately 25°C (77°F).**

3482-5 6/21/89

**WYETH-AYERST**  
LABORATORIES  
Pharmaceuticals, PH 19101

©1991, Wyeth Ayerst Laboratories